LeMaitre Vascular Inc.
Rating
Updated: Sep 18, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Operating worldwide, LeMaitre Vascular, Inc. specializes in the development, distribution, and maintenance of medical devices and implants for treating peripheral vascular disease. Its product portfol...
Latest News
26 days ago · globenewswire.com
LeMaitre to Participate at Upcoming Investor Conferences in SeptemberBURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
1 month ago · seekingalpha.com
LeMaitre Vascular: 31% Drawdown On $0.02 Guidance CutLeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
2 months ago · globenewswire.com
LeMaitre to Participate in the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 ConferenceBURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.
2 months ago · seekingalpha.com
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call TranscriptLeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
2 months ago · marketbeat.com
LeMaitre Vascular Q2 Earnings Call HighlightsLeMaitre Vascular NASDAQ: LMAT reported second-quarter 2026 results marked by 10% organic revenue growth, record operating income and continued expansion of its Artegraft product line, while foreign exchange, Middle East export delays and cardiac allograft supply constraints weighed on sales relative to management's expectations.
2 months ago · zacks.com
LeMaitre Vascular (LMAT) Q2 Earnings and Revenues Lag EstimatesLeMaitre Vascular (LMAT) came out with quarterly earnings of $0.74 per share, missing the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.6 per share a year ago.
2 months ago · globenewswire.com
LeMaitre Q2 2026 Financial ResultsBURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
2 months ago · globenewswire.com
LeMaitre Will Announce Second Quarter 2026 Earnings Results on August 4, 2026BURLINGTON, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2026 financial results on Tuesday, August 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
4 months ago · zacks.com
LeMaitre (LMAT) is an Incredible Growth Stock: 3 Reasons WhyLeMaitre (LMAT) possesses solid growth attributes, which could help it handily outperform the market.
4 months ago · globenewswire.com
LeMaitre to Participate at Upcoming Investor Conferences in JuneBURLINGTON, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will be participating in two upcoming investor conferences in June.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove LMAT